BioCentury | Aug 4, 2008
Company News

LipoNova cancer news

...vaccine in Phase III testing as an adjuvant to treat non-metastatic renal cell carcinoma (RCC). LipoNova GmbH...
BioCentury | Dec 3, 2007
Company News

LipoNova AG deal

...a memorandum of understanding granting an undisclosed non-European company exclusive rights to develop and commercialize LipoNova's...
...in 2008. LipoNova is eligible for milestones and royalties. Further financial terms were not disclosed. LipoNova...
BioCentury | Nov 12, 2007
Clinical News

Reniale: Phase III start

...Next year, LipoNova will start a double-blind, placebo-controlled, international Phase III trial in 800 patients. LipoNova GmbH...
BioCentury | Sep 24, 2007
Clinical News

Reniale: Submit IND

...In 1H08, LipoNova will submit an IND to begin a Phase III trial. LipoNova GmbH , Hannover...
BioCentury | Jul 3, 2006
Finance

Ebb & Flow

...is planning to launch 16 additional kits in the next two years. Looking ahead, although LipoNova...
BioCentury | Jul 19, 2004
Product Development

Selected compounds for RCC

...Product Description Status (milestone) Partner & notes Chiron Proleukin aldesleukin Human recombinant Mkt interleukin-2 (IL-2) LipoNova...
BioCentury | Jul 19, 2004
Product Development

Cancer test bed

..."Selected Compounds for RCC," A5). The most advanced projects are two personalized cancer vaccines from LipoNova GmbH...
...molecules targeting different mechanisms. The AGEN and Wilex compounds are in Phase III studies, while LipoNova...
...tumor cells and antigens to it via vaccination. The most advanced such project is LipoNova's. LipoNova...
Items per page:
1 - 7 of 7
BioCentury | Aug 4, 2008
Company News

LipoNova cancer news

...vaccine in Phase III testing as an adjuvant to treat non-metastatic renal cell carcinoma (RCC). LipoNova GmbH...
BioCentury | Dec 3, 2007
Company News

LipoNova AG deal

...a memorandum of understanding granting an undisclosed non-European company exclusive rights to develop and commercialize LipoNova's...
...in 2008. LipoNova is eligible for milestones and royalties. Further financial terms were not disclosed. LipoNova...
BioCentury | Nov 12, 2007
Clinical News

Reniale: Phase III start

...Next year, LipoNova will start a double-blind, placebo-controlled, international Phase III trial in 800 patients. LipoNova GmbH...
BioCentury | Sep 24, 2007
Clinical News

Reniale: Submit IND

...In 1H08, LipoNova will submit an IND to begin a Phase III trial. LipoNova GmbH , Hannover...
BioCentury | Jul 3, 2006
Finance

Ebb & Flow

...is planning to launch 16 additional kits in the next two years. Looking ahead, although LipoNova...
BioCentury | Jul 19, 2004
Product Development

Selected compounds for RCC

...Product Description Status (milestone) Partner & notes Chiron Proleukin aldesleukin Human recombinant Mkt interleukin-2 (IL-2) LipoNova...
BioCentury | Jul 19, 2004
Product Development

Cancer test bed

..."Selected Compounds for RCC," A5). The most advanced projects are two personalized cancer vaccines from LipoNova GmbH...
...molecules targeting different mechanisms. The AGEN and Wilex compounds are in Phase III studies, while LipoNova...
...tumor cells and antigens to it via vaccination. The most advanced such project is LipoNova's. LipoNova...
Items per page:
1 - 7 of 7